Convalescent Plasma Therapy in Coronavirus Disease 2019: a Case Report and Suggestions to Overcome Obstacles

다국어 초록 (Multilingual Abstract)

Coronavirus disease 2019 (COVID-19) is rapidly spreading around the world, causing much morbidity and mortality everywhere. However, effective treatments or vaccines are still not available. Although convalescent plasma (CP) therapy can be useful in the treatment of COVID-19, it has not been widely used in Korea because of the concerns about adverse effects and the difficulty in matching patients to donors. The use of ABO-incompatible plasma is not contraindicated in treatment, but can be hesitated due to the lack of experience of physicians.
Here, we describe a 68-year old man with COVID-19 who was treated ABO-incompatible plasma therapy; additionally, we comment on the acute side effects associated with ABO mismatch transfusion. To overcome the obstacles of donor-recipient connections (schedule and distance), we propose the storage of frozen plasma, modification of the current Blood Management Law, and the establishment of a CP bank. We suggest that experience gained in CP therapy will be useful for not only the treatment of COVID-19, but also for coping with new emerging infectious diseases.

참고문헌 (Reference)

1 안진영, "Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea" 대한의학회 35 (35): 1-8, 2020

2 Yoo JH, "Uncertainty about the efficacy of remdesivir on COVID-19" 35 (35): e221-, 2020

3 이지현, "Two Cases of Transfusion-related Acute Lung Injury Triggered by HLA and Anti-HLA Antibody Reaction" 대한의학회 25 (25): 1398-1403, 2010

4 Kleinman S, "Toward an understanding of transfusion-related acute lung injury : statement of a consensus panel" 44 (44): 1774-1789, 2004

5 Tay MZ, "The trinity of COVID-19 : immunity, inflammation and intervention" 20 (20): 363-374, 2020

6 Mair-Jenkins J, "The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology : a systematic review and exploratory meta-analysis" 211 (211): 80-90, 2015

7 Casadevall A, "The convalescent sera option for containing COVID-19" 130 (130): 1545-1548, 2020

8 Berséus O, "Risks of hemolysis due to anti-A and anti-B caused by the transfusion of blood or blood components containing ABO-incompatible plasma" 53 (53): 114S-123S, 2013

9 Wang Y, "Remdesivir in adults with severe COVID-19 : a randomised, double-blind, placebo-controlled, multicentre trial" 395 (395): 1569-1578, 2020

10 Armen Yuri Gasparyan, "Perspectives of Immune Therapy in Coronavirus Disease 2019" 대한의학회 35 (35): 1-9, 2020

11 Chapman CE, "National blood service TRALI reduction policies : implementation and effect" 35 (35): 93-96, 2008

12 Ingraham NE, "Immunomodulation in COVID-19" 8 (8): 544-546, 2020

13 Taccone FS, "Hydroxychloroquine in the management of critically ill patients with COVID-19 : the need for an evidence base" 8 (8): 539-541, 2020

14 Khailany RA, "Genomic characterization of a novel SARS-CoV-2" 19 : 100682-, 2020

15 Moore JB, "Cytokine release syndrome in severe COVID-19" 368 (368): 473-474, 2020

16 Rojas M, "Convalescent plasma in Covid-19 : possible mechanisms of action" 19 (19): 102554-, 2020

17 유진홍, "Convalescent Plasma Therapy for Corona Virus Disease 2019: a Long Way to Go but Worth Trying" 대한의학회 35 (35): 1-4, 2020

18 Cao B, "A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19" 382 (382): 1787-1799, 2020

19 Zhu N, "A novel coronavirus from patients with pneumonia in China, 2019" 382 (382): 727-733, 2020

20 Ebert RV, "A clinical study of transfusion reactions : the hemolytic effect of group-O blood and pooled plasma containing incompatible isoagglutinins" 25 (25): 627-638, 1946